Want to see ATR full AI Analyst Report?
Top Page
AptarGroup
(NYSE:ATR)
Select Model
Select Model
Rating:67Neutral
Price Target:
$134.00
▼(-0.92% Downside)
Action:Reiterated
Date:09/22/26
ATR scores as a moderate-quality setup: strong underlying business performance (steady growth, healthy profitability history, and manageable leverage) is tempered by weaker cash conversion and recent margin softness. The stock’s technical picture is the main drag (trading below key moving averages with negative MACD), while valuation and dividend are supportive but not compelling. Earnings-call guidance and long-term product/regulatory milestones are positive, but near-term margin and destocking headwinds plus the Russia administration headline keep the score from moving higher.
Positive Factors
Steady revenue expansion
AptarGroup has delivered sustained top-line expansion across multiple years, indicating continued demand for its dispensing, closure, and delivery solutions. Recurring production programs and broad exposure to consumer and healthcare applications can support durable revenue growth over the coming quarters.
Negative Factors
Recent margin compression
Profitability has weakened despite continued revenue growth, with product mix, lower volumes, ramp-up costs, maintenance, and resin pass-through timing pressuring margins. If these issues persist, they could limit earnings growth and reduce the benefit of AptarGroup’s sales expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue expansion
AptarGroup has delivered sustained top-line expansion across multiple years, indicating continued demand for its dispensing, closure, and delivery solutions. Recurring production programs and broad exposure to consumer and healthcare applications can support durable revenue growth over the coming quarters.
Read all positive factors
AptarGroup (ATR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.05B
Dividend Yield1.52%
Average Volume (3M)477.19K
Price to Earnings (P/E)22.6
Beta (1Y)0.52
Revenue Growth8.93%
EPS Growth-5.14%
CountryUS
Employees14,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)5.60
Shares Outstanding63,581,127
10 Day Avg. Volume449,788
30 Day Avg. Volume477,194
Financial Highlights & Ratios
PEG Ratio3.61
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit8.37
Enterprise Value/Ebitda11.31
Forecast
1Y Price Target
$148.50Price Target Upside9.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)5.49
Revenue Forecast (FY)$3.98B
AptarGroup Business Overview & Revenue Model
Company Description
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (incl...
How the Company Makes Money
AptarGroup makes money primarily by selling engineered components and systems to brand owners and pharmaceutical companies, generating revenue from high-volume, recurring production of dispensing and delivery solutions. Its core revenue streams ge...
AptarGroup Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Neutral
The call presented a mix of clear positives — record quarterly revenue, resilient pharma performance (8% ex‑emergency medicine), strong consumer healthcare growth, product/IP/regulatory milestones, sustainability recognition, and active shareholder returns — alongside tangible near‑term headwinds: emergency medicine destocking (~$65M FY impact), margin compression (EBITDA and EPS declines), operational issues in beauty and closures, higher costs and a higher tax rate. Management emphasized progressive operational improvements and confidence in long‑term growth drivers, but acknowledged short‑term dilution to margins and EPS. On balance the narrative is constructive about the company's fundamentals and future pipeline, while being transparent about cyclical and operational challenges that temper near‑term profitability.Positive Updates
Record Quarterly Revenue
Reported sales increased 6% year-over-year to $1.0 billion, representing a new quarterly record; core sales (ex-currency and acquisitions) rose 1%.
Negative Updates
Adjusted EPS and EBITDA Declines
Adjusted EPS decreased to $1.42 from $1.68 year-over-year (down ~15% at comparable exchange rates); adjusted EBITDA was $213M, down 3% YoY, and adjusted EBITDA margin fell to 20.7% from 22.6% (190 bps compression).
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue
Reported sales increased 6% year-over-year to $1.0 billion, representing a new quarterly record; core sales (ex-currency and acquisitions) rose 1%.
Read all positive updates
Company Guidance
Aptar guided third‑quarter adjusted EPS of $1.45–$1.53, assuming an effective tax rate of 22.5%–24.5% and an EUR/USD of 1.14 (Q2 average was 1.16, implying a quarter‑over‑quarter FX headwind); for full‑year 2026 management reiterated capital investments of $260–$280 million and depreciation & amortization of $310–$320 million, noted the roughly $65 million emergency‑medicine destocking headwind (about two‑thirds already incurred in H1 with the remaining one‑third primarily in H2 and expected to abate by Q4), and framed the outlook against a quarter‑end cash balance of $190 million, net debt of $1.2 billion (1.49x leverage), year‑to‑date free cash flow of $99 million, cash from operations of $222 million less net capex of $123 million, and $212 million returned to shareholders year‑to‑date (including 1.1 million shares repurchased for $150 million).AptarGroup Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.93B | 3.78B | 3.58B | 3.49B | 3.32B | 3.23B |
| Gross Profit | 1.11B | 1.12B | 1.36B | 1.26B | 1.16B | 1.16B |
| EBITDA | 822.22M | 831.48M | 777.45M | 663.84M | 609.41M | 586.79M |
| Net Income | 362.52M | 392.79M | 374.54M | 284.49M | 239.29M | 244.10M |
Balance Sheet | ||||||
| Total Assets | 5.13B | 5.25B | 4.43B | 4.45B | 4.20B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 197.27M | 409.53M | 226.18M | 223.64M | 141.73M | 123.67M |
| Total Debt | 1.43B | 1.53B | 1.08B | 1.18B | 1.22B | 1.24B |
| Total Liabilities | 2.46B | 2.54B | 1.95B | 2.13B | 2.14B | 2.16B |
| Stockholders Equity | 2.63B | 2.67B | 2.47B | 2.31B | 2.05B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | 310.39M | 299.58M | 349.22M | 256.84M | 163.00M | 55.51M |
| Operating Cash Flow | 583.48M | 570.00M | 643.41M | 575.24M | 478.62M | 363.44M |
| Investing Cash Flow | -325.43M | -330.64M | -396.72M | -324.46M | -295.64M | -457.24M |
| Financing Cash Flow | -225.53M | -78.26M | -225.34M | -171.55M | -162.10M | -81.52M |
AptarGroup Technical Analysis
Positive
135.24
Price Trends
126.12
Positive
126.20
Positive
126.25
Positive
Market Momentum
0.29
Negative
58.24
Neutral
87.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATR, the sentiment is Positive. The current price of 135.24 is above the 20-day moving average (MA) of 122.55, above the 50-day MA of 126.12, and above the 200-day MA of 126.25, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 58.24 is Neutral, neither overbought nor oversold. The STOCH value of 87.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATR.
AptarGroup Risk Analysis
AptarGroup disclosed 28 risk factors in its most recent earnings report. AptarGroup reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AptarGroup Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $27.60B | 49.83 | 18.51% | 0.24% | 12.42% | 17.07% | |
68 Neutral | $5.32B | 36.24 | 8.94% | 0.32% | 14.73% | 7.43% | |
67 Neutral | $8.05B | 22.60 | 13.52% | 1.52% | 8.93% | -5.14% | |
65 Neutral | $54.18B | 59.91 | 3.79% | 2.00% | -2.56% | -40.38% | |
64 Neutral | $11.69B | -20.61 | -10.34% | ― | -1.57% | -183.83% | |
57 Neutral | $13.08B | -12.41 | -16.60% | 0.16% | 5.36% | -632.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ATR
AptarGroup
126.55
-0.78
-0.61%
BAX
Baxter International
25.30
2.18
9.41%
BDX
Becton Dickinson
198.91
55.51
38.71%
WST
West Pharmaceutical Services
392.15
105.82
36.96%
AVTR
Avantor
17.29
2.18
14.43%
STVN
Stevanato Group
19.49
-6.40
-24.71%
AptarGroup Corporate Events
Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance
AptarGroup Faces Russian External Administration, Limited Financial Impact
Negative
Sep 21, 2026
On September 21, 2026, a decree by the President of the Russian Federation placed AptarGroup’s Russian subsidiary, OOO Aptar Vladimir, under temporary external administration, prompting the company to begin assessing the situation and its av...
Executive/Board Changes
AptarGroup Names Interim Chief Accounting Officer Ackerman
Neutral
Sep 10, 2026
On September 4, 2026, AptarGroup’s Vice President and Chief Accounting Officer, Aditya J. Gandhi, tendered his resignation, effective September 11, 2026, to pursue an opportunity outside the greater Chicago area. The company stated his depar...
Executive/Board Changes
AptarGroup Names New CEO and Board Member
Neutral
Sep 1, 2026
On August 29, 2026, AptarGroup’s board expanded its membership from ten to eleven directors and appointed newly named President and Chief Executive Officer Gael Touya to the board, effective September 1, 2026. His term will run until the 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.